secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001104659-26-022940
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport FY2025 revenue $176.2M (+12% YoY) beats guidance; FY2026 outlook $190-194M
--------------------------------------------------------------------------------

- FY2025 revenue $176.2M, up 12% YoY; Q4 revenue $45.5M, up 10% YoY.
- Loss from continuing operations $34.0M; adjusted EBITDA from cont. ops -$5.8M (vs -$17.8M).
- Commercial cell & gene therapy revenue $33.4M (+29% YoY); supported 760 clinical trials.
- Life Sciences Services revenue $96.5M (+18%); BioStorage/BioServices up 22% to $18.4M.
- Cash & investments $411.2M; repurchased 1.34M shares at avg $7.45 for $10.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465926022940/0001104659-26-022940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465926022940/tm267876d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-022940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer